Clinical trials: Severe ARDS
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
ARDS, AHRF
HemodynamIc eFfects of Lung Collapse and overdIstension During ARDS
The management ARDS relies on ventilatory strategies aimed at limiting ventilator-induced lung injury (VILI). The setting of PEEP is still subject of debate, as randomized clinical trials comparing standardized higher versus…
- Trial name
- HI-FIVE (NCT07423520)
- Testing
- Change in PEEP
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial.
- Conditions
- SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Mutation
- Trial name
- SEVARVIR (NCT05162508)
- Testing
- Nasopharyngeal swab
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Respiratory Distress Syndrome
A Comparison of Optimal PEEP Determination Guided by EIT and G5 Device in Moderate and Severe ARDS Patients
To Select the Optimal Positive End-expiratory Pressure in Moderate and Severe Acute Respiratory Distress Syndrome Patients by Using: 1. the novel Non-invasive Electrical Impedance Tomography Guided Method 2.
- Trial name
- NCT03112512
- Testing
- optimal PEEP guided by EIT, optimal PEEP guided by G5 ventilator
- Where
- Taiwan
- Volunteers
- 88 people
- Sponsor
- Mei-Yun Chang
Human Anaplasmosis
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace.
- Trial name
- ANARETRO (NCT07312474)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
ARDS (Moderate or Severe)
FAPI PET/CT to Detect Fibroblast Activity in Non-resolving ARDS
Of patients requiring mechanical ventilation in the ICU 23% meet criteria of the Acute Respiratory Distress Syndrome (ARDS). Mortality of this syndrome remains high (35-46%) in moderate and severe ARDS.
- Trial name
- FAPI ARDS (NCT06691464)
- Testing
- PET
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Hypoxemia, Ards
Effectiveness of Low Volume and Low Pressure in Severe Hypoxemic Patients
The present study set up to answer two questions: (a) "how low tidal volume must be to provide protective ventilatory settings able to minimize the risk of death due to Ventilator-Induced Lung Injury (VILI)?"; (b) "if protection…
- Trial name
- avengARDS (NCT06513299)
- Testing
- low tidal volume, high tidal volume, low driving pressure
- Where
- Italy
- Volunteers
- 4,300 people
- Sponsor
- Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
Infection, Coronavirus, Respiratory Failure
Use of Angiotensin-(1-7) in COVID-19
The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the…
- Trial name
- NCT04633772
- Testing
- Angiotensin-(1-7)
- Where
- 2 sites in Brazil
- Volunteers
- 112 people
- Sponsor
- Erasme University Hospital
Acute Respiratory Distress Syndrome, Pneumonia
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
- Conditions
- Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
- Trial name
- iGRASP (NCT02601365)
- Testing
- Sargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
- Sponsor
- Milton S. Hershey Medical Center
Respiratory Distress Syndrome, Adult
New Lung Ventilation Strategies Guided by Transpulmonary Pressure in VV-ECMO for Severe ARDS
Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe acute respiratory distress syndrome (ARDS).
- Trial name
- NCT02439151
- Testing
- New lung ventilation strategy, Conventional ventilation strategy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Rui Wang
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ARDS (Moderate or Severe), Acute Hypoxemic Respiratory Failure
PEEP-induced Effects on Respiratory dRivE and EFfort
Rationale: In patients with acute hypoxemic respiratory failure (AHRF), preserving spontaneous breathing during mechanical ventilation offers physiological benefits, but also carries risks.
- Trial name
- REEF (NCT07203781)
- Testing
- PEEP level changes
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
COVID-19, Acute Respiratory Distress Syndrome
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Virus; Pneumonia, Acute Lung Injury
- Trial name
- NCT04331613
- Testing
- CAStem
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese Academy of Sciences
COVID-19
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
COVID-19 associated mortality remains high despite the advances in therapeutics such as dexamethasone. The severity of COVID-19 results from direct viral cytotoxicity, and the inflammatory response, which is associated with a…
- Trial name
- EPIC (NCT05182515)
- Testing
- Therapeutic plasma exchange
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
Coronavirus Infection, COVID
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus Infection, COVID, SARS-CoV 2, Respiratory Failure
- Trial name
- CYCOV-II (NCT04385771)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Dr. Alexander Supady
Severe Acute Respiratory Distress Syndrome, Refractory Hypoxemia
ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure
Extracorporeal membrane oxygenation (ECMO) had been used to treat refractory hypoxemia associated with acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04031794
- Testing
- Extra Corporeal Membrane Oxygenator (ECMO)
- Where
- Thailand
- Volunteers
- 250 people
- Sponsor
- Mahidol University
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Little Lungs Study
This clinical trial is being done to evaluate the safety and clinical response of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age.
- Trial name
- NCT06855043
- Testing
- Calfactant, Budesonide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies